NO951646L - Nye merkaptoacetylamid-bisykliske laktamderivater som er anvendbare som inhibitorer av enkefalinase og ACE - Google Patents

Nye merkaptoacetylamid-bisykliske laktamderivater som er anvendbare som inhibitorer av enkefalinase og ACE

Info

Publication number
NO951646L
NO951646L NO951646A NO951646A NO951646L NO 951646 L NO951646 L NO 951646L NO 951646 A NO951646 A NO 951646A NO 951646 A NO951646 A NO 951646A NO 951646 L NO951646 L NO 951646L
Authority
NO
Norway
Prior art keywords
enkephalinase
ace
inhibitors
lactam derivatives
pct
Prior art date
Application number
NO951646A
Other languages
English (en)
Norwegian (no)
Other versions
NO951646D0 (no
Inventor
Gary Alan Flynn
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO951646D0 publication Critical patent/NO951646D0/no
Publication of NO951646L publication Critical patent/NO951646L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO951646A 1992-10-30 1995-04-28 Nye merkaptoacetylamid-bisykliske laktamderivater som er anvendbare som inhibitorer av enkefalinase og ACE NO951646L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96877092A 1992-10-30 1992-10-30
PCT/US1993/009001 WO1994010193A1 (en) 1992-10-30 1993-09-23 Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace

Publications (2)

Publication Number Publication Date
NO951646D0 NO951646D0 (no) 1995-04-28
NO951646L true NO951646L (no) 1995-06-23

Family

ID=25514751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951646A NO951646L (no) 1992-10-30 1995-04-28 Nye merkaptoacetylamid-bisykliske laktamderivater som er anvendbare som inhibitorer av enkefalinase og ACE

Country Status (21)

Country Link
US (1) US5635502A (el)
EP (1) EP0669936B1 (el)
JP (1) JP3420766B2 (el)
KR (1) KR100311166B1 (el)
AT (1) ATE197714T1 (el)
AU (1) AU673857B2 (el)
CA (1) CA2146238C (el)
DE (1) DE69329701T2 (el)
DK (1) DK0669936T3 (el)
ES (1) ES2155852T3 (el)
FI (1) FI110263B (el)
GR (1) GR3035416T3 (el)
HU (1) HUT71243A (el)
IL (1) IL107413A (el)
MX (1) MX9306758A (el)
NO (1) NO951646L (el)
NZ (1) NZ256589A (el)
PT (1) PT669936E (el)
TW (1) TW327172B (el)
WO (1) WO1994010193A1 (el)
ZA (1) ZA937912B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646276A (en) * 1992-05-13 1997-07-08 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
CA2140553A1 (en) * 1993-06-11 1994-12-22 Hitoshi Oinuma Amino acid derivative
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
ES2168355T3 (es) * 1994-02-14 2002-06-16 Merrell Pharma Inc Derivados de bisulfuro de indano-2-mercaptoacetilamida utiles como inhibidores de la encefalinasa.
EP0750631B1 (en) * 1994-02-14 2000-04-05 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
EP0746566A1 (en) * 1994-02-14 1996-12-11 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
PT719779E (pt) * 1994-07-18 2004-04-30 Eisai Co Ltd Derivado de tiazolo¬3,2|azepina substituido
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US6020331A (en) * 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6699869B1 (en) 1995-03-24 2004-03-02 Myriad Genetics Inc. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
AU750122C (en) 1998-06-17 2003-02-27 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
EP1169311A4 (en) * 1999-03-22 2004-09-15 Rhode Island Education COMBINATORIAL OXAZOLE AND THIAZOLE BANKS
US7015212B1 (en) 1999-05-12 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Thiazepine inhibitors of HIV-1 integrase
JP2005526722A (ja) 2002-02-14 2005-09-08 ミリアド・ジェネティックス・インコーポレイテッド β−シートミメティックならびにそれに関連する組成物および方法
FR2984716B1 (fr) 2011-12-22 2013-12-27 Essilor Int Dispositif et procede de determination d'au moins un parametre de refraction oculaire objective d'un sujet en fonction d'une pluralite de directions de regard
EP2925764B1 (en) 2012-11-30 2023-03-01 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334095A (en) * 1965-02-16 1967-08-01 Sandoz Ag Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en) * 1965-03-25 1967-08-01 Sandoz Ag Sedatives
GB1525845A (en) * 1976-07-30 1978-09-20 Ucb Sa 1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en) * 1980-02-26 1986-07-23 Wyeth John & Brother Ltd Novel processes for preparing proline derivatives and analogous compounds
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
PT82468B (en) * 1985-04-30 1988-03-23 Lilly Co Eli Process for preparing 7-substituted bycyclic pyrazolidinones
FI90418C (fi) * 1986-04-04 1994-02-10 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten perhydrotiatsepiini- ja perhydroatsepiinijohdannaisten valmistamiseksi
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
US4973585A (en) * 1986-06-13 1990-11-27 Merrell Dow Pharmaceuticals Tricyclic lactams active as antihypertensive agents
CA1337654C (en) * 1986-06-13 1995-11-28 Gary A. Flynn Fused tricyclic lactams as antihypertensive agents
GB8629875D0 (en) * 1986-12-15 1987-01-28 Hoffmann La Roche Pyridazodiazepine derivatives
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
GB8926512D0 (en) * 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
AU7168091A (en) * 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
CA2057786C (en) * 1990-12-21 2002-06-18 Gary A. Flynn Amino and nitro containing tricyclic compounds useful as inhibitors or ace
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0533084A1 (en) * 1991-09-16 1993-03-24 Schering Corporation Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation
GB9204588D0 (en) * 1992-03-03 1992-04-15 Ferguson Scot Ltd Containers
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds

Also Published As

Publication number Publication date
NZ256589A (en) 1996-05-28
JP3420766B2 (ja) 2003-06-30
DE69329701T2 (de) 2001-05-10
EP0669936A1 (en) 1995-09-06
FI110263B (fi) 2002-12-31
AU673857B2 (en) 1996-11-28
US5635502A (en) 1997-06-03
ZA937912B (en) 1994-06-01
CA2146238A1 (en) 1994-05-11
ES2155852T3 (es) 2001-06-01
IL107413A0 (en) 1994-01-25
HUT71243A (en) 1995-11-28
NO951646D0 (no) 1995-04-28
DK0669936T3 (da) 2001-02-05
HU9501239D0 (en) 1995-06-28
WO1994010193A1 (en) 1994-05-11
CA2146238C (en) 2001-03-13
FI952014A0 (fi) 1995-04-27
FI952014A (fi) 1995-04-27
DE69329701D1 (de) 2000-12-28
EP0669936B1 (en) 2000-11-22
JPH08502746A (ja) 1996-03-26
TW327172B (en) 1998-02-21
IL107413A (en) 1999-08-17
GR3035416T3 (en) 2001-05-31
PT669936E (pt) 2001-04-30
KR950704349A (ko) 1995-11-20
MX9306758A (es) 1994-07-29
KR100311166B1 (ko) 2002-02-28
AU5136293A (en) 1994-05-24
ATE197714T1 (de) 2000-12-15

Similar Documents

Publication Publication Date Title
NO951646D0 (no) Nye merkaptoacetylamid-bisykliske laktamderivater som er anvendbare som inhibitorer av enkefalinase og ACE
DE69309670D1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
DE69327541D1 (en) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
ZA953981B (en) New azolidinediones as antihyperglycemic agents
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO974690D0 (no) Nye triazoloner som inhibitorer av apolipoprotein B-syntesen
DK0652879T3 (da) 1-Azaadamantanderivater som 5-HT4-agonister eller -antagonister og/eller 5-HT3-antagonister
TW340844B (en) Amide derivatives
ES2128572T3 (es) Utilizacion de los derivados de cefem como agentes antimetastaticos.
AU5674894A (en) Azanoradamantanes
NO963367D0 (no) Nye mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
DK0625146T3 (da) Nye syreanhydrider samt fremstilling og anvendelse heraf
YU200791A (sh) Trifluorometil 1-karba (1-detia) cefemi
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
ES8301199A1 (es) Procedimiento para la preparacion de un derivado fluorado de diaminobutano que es enlubidor de transaminasa de acido gamma- aminobutirico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application